Pretty much everyone in the developed world has heard of Viagra and Cialis, both drugs used to treat erectile dysfunction. There have been many television ad campaigns dedicated to these drugs and they’re flying off shelves across the country. While pharmaceutical companies have yet to create a pill for women, BioSante Pharmaceuticals has created a transdermal gel that contains testosterone which increases the sex drive in women. The gel, called LibiGel, will be submitted to the FDA for review in 2012.

In addition to LibiGel, BioSante Pharmaceuticals has created a number of promising drugs and vaccines. It has created a low-dose estrogen transdermal gel for the treatment of hot flashes in menopausal women as well as a testosterone gel for treating men with low testosterone levels. Perhaps the most promising products BioSante Pharmaceuticals has created are vaccines for a variety of cancers, including: prostate, pancreatic and breast cancer, melanoma and leukemia. While none of these vaccines are currently available to the public, they are all undergoing FDA clinical trials and are showing promising results. The company currently has five cancer vaccines in late human clinical trials and two that are undergoing preclinical or early human trials (BioSante).

It is estimated that one in every four deaths in the U.S. are cancer related, making cancer second only to heart disease in terms of mortality (American Cancer Society); and nearly one of every two Americans will be diagnosed with some form of cancer in their lifetime. Considering these statistics, it is critical that pharmaceutical and biotechnology companies should conduct research for effective treatments and preventative vaccines. With a total of seven cancer vaccines in various stages of clinical trials, BioSante is at the forefront of cancer prevention and could prove to be integral to the fight against cancer.